Professional Documents
Culture Documents
Valio Dation
Valio Dation
( JPAVG )
Guide Guide
HVAC Validation
INTRODUCTION
HVAC stands for Heating, Ventilating & Air Conditioning
It includes a variety of active mechanical/electrical systems employed
to provide thermal control in buildings.
H- Heating system adds thermal energy to a space or building in order
to maintain some selected air temperature that would otherwise not be
achieved due to heat loss to the exterior environment.
V- Ventilating system is intended to introduce air to or remove air from
a space to move air without changing its temperature. Ventilating
systems may be used to improve indoor air quality or to improve
thermal comfort.
AC- Air Conditioning system removes thermal energy from a space or
building to maintain some selected air temperature that would
otherwise not be achieved due to heat gain from interior heat sources
and the exterior environment.
As per ASHRAE (American Society of Heating, Refrigerating & Air
conditioning Engineers), HVAC system should fulfil four objectives:
o Control air temperature
o Control air humidity
o Control air circulation
o Control air quality
www.jpavg.com 1 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
1 2
3 4
www.jpavg.com 2 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
Calculation of ACPH:
ACPH = (Airflow discharge in room 60) Room volume
Air flow discharge (m3/minute) = Air velocity of HEPA filter (m/s) Filter area
(m2) x 60
Acceptance Criteria:
o For Unidirectional airflow system (Grade A):
As per EU & WHO (Technical Report Series No. 961) : 0.36 – 0.54 m/s
As per Schedule M : 0.3 m/s ± 20% (for vertical flows) and
0.45 m/s ± 20% (for horizontal flows)
o For Non-unidirectional airflow system (Grade B, C & D), the ACPH should
be appropriate for the size of the room and the equipment and personnel
present in it.
As per Schedule M, the minimum ACPH for Grade B and Grade C areas
shall not be less than 20 air changes per hour in a room with good air
flow pattern and appropriate HEPA filters.
www.jpavg.com 3 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
www.jpavg.com 4 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
Measurement shall be done at working height and in two states i. e. “at rest” &
“in operation”.
No. of sampling location= X i. e. square root of Room area in square meter
Rationale for sampling location shall be dependent on man movement, material
movement, area of product exposure, manual intervention and location likely to
have more air borne particles like return riser.
Sample Volume and Sampling time per location:
* Note: As per ISO 14644-1, the volume sampled at each location shall be at least
2 L with minimum sampling time at each location of 1 minute.
www.jpavg.com 5 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
Acceptance Criteria:
o As per EU Guideline & WHO (TRS No. 961)
At rest In operation
Grade
0.5µ 5.0 µ 0.5µ 5.0 µ
A 3520 20 3520 20
B 3520 29 352000 2900
C 352000 2900 3520000 29000
D 3520000 29000 Not defined
o As per Schedule M:
At rest In operation
Grade
0.5µ 5.0 µ 0.5µ 5.0 µ
A 3520 29 3520 29
B 35200 293 352000 2930
C 352000 2930 3520000 29300
D 3520000 29300 Not defined
When the number of locations to be sampled is more than one and less than ten,
compute 95% upper confidence limit (UCL) from the average particle
concentrations for all locations as per formula given below.
UCL = X + (t0.95 * SD / n )
Where,
X is the overall mean of the location averages.
t0.95 represents the 95th percentile of the t distribution, with (n-1) degrees
of the freedom.
SD is the standard deviation of the location averages.
n is square root of number of individual location averages.
www.jpavg.com 6 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
o As per Schedule M:
www.jpavg.com 7 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
RECOVERY STUDY
This test is performed to determine the ability of the installation to eliminate
airborne particles.
This test is only important and recommended for non-unidirectional airflow
systems because the recovery performance is a function of air re-circulation
ratio, inlet-outlet airflow geometry, thermal conditions and the air distribution
characteristics within the controlled zone.
This test should be carried out in at rest state.
As per ISO 14644-3, this test is not recommended for class 8 (Grade D) and 9.
Procedure:
Measure the clean room or clean zone air borne non-viable particle counts at rest
condition.
The cleanroom area to be examined should be then contaminated with an
aerosol while the air-handling units are in operation.
Commence measurements at 1 min intervals. Note the time when the particle
concentration reaches the 100 x target concentration threshold (t100n).
Note the time when the particle concentration reaches the target cleanliness
level (tn).
Recovery Time: tn - t100n
Acceptance Criteria:
As per WHO (TRS No. 961), the recovery period should not be more than
15-20 min.
www.jpavg.com 8 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
Acceptance Criteria:
o The temperature and relative humidity depend on the product and nature
of the operations carried out.
o As per Schedule M, temperature and humidity in the aseptic areas shall
not exceed 27 °C and relative humidity 55%, respectively unless there are
product specific requirements.
Acceptance Criteria:
o Light level: NLT 300 Lux at working height
o Noise level: NMT 85 db at working height
www.jpavg.com 9 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
FREQUENCY OF REVALIDATION
Frequency
Test
As per ISO As per Schedule M
Air Velocity 12 months 06 months
Grade A: 06 months
Non Viable Particle count 06 months
Grade B,C & D: 12 months
Recovery 24 months -
www.jpavg.com 10 of 11
Journal of Pharma Analytica & Validation Guide
( JPAVG )
Guide Guide
REFERENCES
ISO 14644-3, Cleanrooms and associated controlled environments- Test methods
EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and
Veterinary Use, Volume 4, Annexure 1
WHO Technical Report Series, No. 961 (2011), Annexure 6
Schedule M
www.jpavg.com 11 of 11